Update in the Management of Hepatitis C: What Does the Future Hold
|
|
- Anne Robbins
- 6 years ago
- Views:
Transcription
1 Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana University School of Medicine 975 W. Walnut, IB 327 Indianapolis, IN phone fax pkwo@iu.edu The components of treatment in HCV infection XRBV NS5a X PEG IFN NS5b NS3 NS5b NNI Copyright 2014 American College of Gastroenterology 1
2 Direct-Acting Antiviral Agents (DAAs) - Key Characteristics NS3 /4A Inhibitors (Protease inhibitor PI) High potency Limited genotypic coverage Low barrier to resistance NS5B Nucleos(t)ide Inhibitors (NI) Intermediate potency Pan genotypic coverage High barrier to resistance NS5A Inhibitors High potency Multi-genotypic coverage Low barrier to resistance NS5B Non Nucleoside Inhibitors (NNI) Intermediate potency Limited genotypic coverage Low barrier to resistance Genotype 1 Treatment-Naive Patients Interferon eligible Sofosbuvir (400 mg) and weight-based RBV ( mg) plus weekly PEG for 12 weeks regardless of subtype (1a or 1b) Alternative Regimen: simeprevir (150 mg) for 12 weeks and weight-based RBV ( mg) plus weekly PEG for 24 weeks for genotype 1b or genotype 1a infection in without Q80 polymorphism Patients who are NOT eligible to receive IFN: Sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based RBV ( mg) for 12 weeks regardless of subtype (1a or1b) Daily sofosbuvir (400 mg) and weight-based RBV ( mg) regardless of subtype Copyright 2014 American College of Gastroenterology 2
3 The current standard of care: Genotype 1 patients who have failed therapy Patients who failed therapy without protease inhibitor regardless of IFN eligibility Sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based RBV ( mg) for 12 weeks regardless of subtype (1a or 1b) Alternative Regimen: simeprevir (150 mg) for 12 weeks and weight-based RBV ( mg) plus weekly PEG for 48 weeks regardless of subtype (1a or 1b), no Q80K testing Alternative Regimen including those who have failed protease inhibitor: and can tolerate IFN: Sofosbuvir (400 mg) and weight-based RBV ( mg) plus weekly PEG for weeks regardless of subtype (1a or 1b) NEUTRINO Study: SVR12 by HCV Genotype (%) s with HCV RNA <LLOQ ( Patients 295/ /292 27/28 7/7 Overall GT 1 GT 4 GT 5,6 Error bars represent 95% confidence intervals. Lawitz E, et al. 48th EASL; Amsterdam, Netherlands; April 24-28, Abst Copyright 2014 American College of Gastroenterology 3
4 COSMOS Study: Simeprevir + Sofosbuvir ± RBV in GT 1, Treatment-naïve and Prior Null Responder SVR12 Non-VF Relapse 2/30 2/27 1/14 3% 2% 3/87 2/87 SVR 93% 100% 93% 93% 94% 28/30 16/16 25/27 13/14 82/87 SMV/SOF + RBV SMV/SOF Non-VF, patients who did not achieve SVR12 for reasons other than virologic failure SMV/SOF + RBV SMV/SOF SMV/SOF±RBV 24 weeks 12 weeks Overall ITT, intent-to-treat; Non-VF, Non-virologic failure; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR12, sustained virologic response 12 weeks after planned treatment end The components of SVR in HCV with nucleotide polymerase inhibitor + NS5a for genotype 1 NS5b NS5a Copyright 2014 American College of Gastroenterology 4
5 Sofosbuvir 400 mg/ledipasvir 90 mg approved for genotype 1 infection 10/10/14 Patient Population Recommended Treatment Duration Treatment-naïve with or without cirrhosis 12 weeks* Treatment-experienced** without cirrhosis 12 weeks Treatment-experienced** with cirrhosis 24 weeks *SOF/LDV for 8 weeks can be considered in treatment-naïve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL **Treatment-experienced patients who have failed treatment with either peginterferon alfa + ribavirin or an HCV protease inhibitor + peginterferon alfa + ribavirin. Study Design GT 1 Treatment-Naïve (ION-1) Wk 0 Wk 12 Wk 24 Wk 36 LDV/SOF SVR12 LDV/SOF + RBV LDV/SOF LDV/SOF + RBV GT 1 HCV treatment-naïve patients in Europe and USA Broad inclusion criteria Targeted 20% enrollment of patients with cirrhosis No upper age or BMI limit Platelet count 50,000/mm 3, no neutrophil minimum 865 patients randomized 1:1:1:1 across four arms Stratified by HCV subtype (1a or 1b) and cirrhosis Afdhal et al. NEJM 2014;370: Copyright 2014 American College of Gastroenterology 5
6 SVR12: Absence of Cirrhosis vs Cirrhosis GT 1 Treatment-Naïve (ION-1) Absence of Cirrhosis Cirrhosis SVR 179/180 32/34 178/184 33/33 181/184 31/33 179/181 36/36 LDV/SOF LDV/SOF + RBV LDV/SOF LDV/SOF + RBV Error bars represent 95% confidence intervals. 12 Weeks 24 Weeks GT 1 Treatment-Naïve (ION-3) : 8 weeks of therapy with SOD/LDV leads to high SVR rates in non-cirrhotic naïve patients Wk 0 Wk 8 Wk 12 Wk 20 Wk 24 LDV/SOF SVR12 LDV/SOF + RBV SVR12 LDV/SOF SVR12 GT 1 treatment-naïve patients without cirrhosis Broad inclusion criteria No upper age or BMI limit Opiate substitution therapy allowed 647 patients randomized 1:1:1 across three arms Stratified by HCV subtype (1a or 1b) Kowdley KV et al. NEJM 2014; 370: Copyright 2014 American College of Gastroenterology 6
7 SVR12 (%) ION 3: SVR12 With 8 or 12 Wks SOF/LDV ± RBV in Tx-Naive Non-cirrhotic Patients P =.52 P =.70 P = Post hoc analysis notes high SVR rates in those with HCV RNA < 6 X 10 6 IU/ml Treatment Duration SOF/LDV SVR (%) with Baseline HCV RNA <6 million IU/mL 20 8 wks 97 (119/123) 0 202/ / / wks 96 (126/131) SOF/LDV SOF/LDV + RBV SOF/LDV 8 Wks 12 Wks SVR12 rates did not differ by GT1a vs GT1b in any treatment arm Virologic failure: 23 relapses (11 in 8-wk SOF/LDV, 9 in 8-wk SOF/LDV/RBV, 3 in 12-wk SOF/LDV) GT 1 Treatment-Experienced (ION-2): Study Design Wk 0 Wk 12 Wk 24 Wk 36 LDV/SOF LDV/SOF + RBV SVR12 SVR12 LDV/SOF LDV/SOF + RBV SVR12 SVR12 GT 1 HCV patients who had failed prior IFN-based therapy, including regimens containing a NS3/4A protease inhibitor Broad inclusion criteria Targeted 20% enrollment of patients with cirrhosis No upper age or BMI limit Platelet count 50,000/mm3, no neutrophil minimum 440 patients randomized 1:1:1:1 across four arms Stratified by HCV subtype (1a or 1b), cirrhosis, prior treatment response Afdhal N, et al. N Engl J Med. 2014;370: Copyright 2014 American College of Gastroenterology 7
8 ION 2: SVR12 With 12 or 24 Wks of SOF/LDV ± RBV by Cirrhosis Status 24 weeks duration for cirrhosis patients SVR12 (%) / 87 19/ 22 89/ 89 18/ 22 86/ 87 22/ 22 88/ 89 22/ 22 LDV/SOF LDV/SOF + RBV LDV/SOF LDV/SOF + RBV 12 Wks 24 Wks No cirrhosis Cirrhosis SVR12 rates were significantly lower in cirrhotic vs noncirrhotic patients in the pooled 12-wk arms Previous treatment with protease inhibitor or did not matter Afdhal N, et al. N Engl J Med. 2014;370: The components of SVR in HCV: High SVR rates without a nucleotide polymerase inhibitor coming soon NS3 NS5b NNI NS5a RBV Copyright 2014 American College of Gastroenterology 8
9 Paritaprevir/ RTV Ombitasvir + Dasabuvir + RBV in HCV Genotype 1 (SAPPHIRE-I): Phase 3 Study Double-Blind Key eligibility criteria HCV genotype 1 Treatment-naïve No cirrhosis No HIV or HBV Double-Blind li PTV/RTV/OMB + DBV BID +RBV BID (n=473) Placebo* (n=158) Open-Label PTV/RTV/OMB + DBV BID +RBV BID (n=158) Week Paritaprevir/ RTV (150/100 mg) co-formulated with Ombitasvir (25 mg) and administered once-daily daily. Dasabuvir (250 mg) + RBV (weight-based dosing) administered twice-daily. *After week 12, placebo patients received open-label Paritaprevir/ RTV Ombitasvir + Dasabuvir + RBV for 12 weeks. Primary outcome: SVR12. Feld JJ, et al. NEJM 2014; 370: SAPPHIRE-I Results: ITT SVR12 Rates 96.2% 95.3% 98.0% SVR12, % Patients 455/ / / All Patients GT1a GT1b Copyright 2014 American College of Gastroenterology 9
10 Paritaprevir/ RTV Ombitasvir + Dasabuvir ± RBV in GT1 Patients Without Cirrhosis: Is RBV Necessary? (PEARL III and PEARL IV) Wk 12 SVR12, % Wk 24 PEARL III DAA-naive pts with GT1a HCV (N = 305) PEARL IV DAA-naive pts with GT1b HCV (N =419) PTV/RTV/OMB + DBV + RBV (n =100) PTV/RTV/OMB + DBV + placebo (n = 205) PTV/RTV/OMB + DBV + RBV (n = 210) PTV/RTV/OMB + DBV + placebo (n = Ferenci P et al. N Engl J Med 2014;370: Paritaprevir/ RTV Ombitasvir + Dasabuvir + RBV in HCV Genotype 1 non-responders (SAPPHIRE-II): Phase 3 Study Double-Blind Key eligibility criteria HCV genotype 1 Treatment nonresponder (relapse, partial or null response No cirrhosis No HIV or HBV Double-Blind PTV/RTV/OMB + DBV BID +RBV BID (n=297) Placebo* (n=97) Open-Label PTV/RTV/OMB + DBV BID +RBV BID Week Paritaprevir/ RTV (150/100 mg) co-formulated with Ombitasvir (25 mg) and administered once-daily. Dasabuvir (250 mg) + RBV (weight-based dosing) administered twice-daily. *After week 12, placebo patients received open-label Paritaprevir/ RTV Ombitasvir + Dasabuvir + RBV for 12 weeks. Primary outcome: SVR12. Zeuzem S, et al. NEJM 2014;370: Copyright 2014 American College of Gastroenterology 10
11 SAPPHIRE-II Results: ITT SVR12 Rates >95% in All Prior Peginterferon/Ribavirin Response Groups 95.3% 100% 95.2% SVR12, % Patients 82/ /65 139/ Prior Relapse Prior Partial Response Prior Null Response Paritaprevir/ RTV Ombitasvir + Dasabuvir + RBV in HCV Genotype 1 Cirrhosis (TURQUOISE-II): Phase 3 Study Key eligibility criteria HCV genotype 1 Treatment-naïve and treatmentexperienced Compensated cirrhosis (Child- Pugh score <6) HCV RNA >10K IU/mL PTV/RTV/OMB + DBV BID +RBV BID (n=208) PTV/RTV/OMB + DBV BID +RBV BID (172) Week No HIV or HBV Paritaprevir/ RTV (150/100 mg) co-formulated with Ombitasvir (25 mg) and administered once-daily. Dasabuvir (250 mg) + RBV (weight-based dosing) administered twice-daily. Primary outcome: SVR12. Zeuzem S, et al. NEJM 2014;370: Copyright 2014 American College of Gastroenterology 11
12 TURQUOISE-II Results: ITT SVR12 Rates of 92% to 96% P=0.089 SVR12, % Patients SVR 80% in 1a null Responders who Received 12 weeks of therapy 191/ Weeks / Weeks The current standard of care: Genotypes 2/3 HCV genotype 2, regardless of eligibility for IFN therapy or treatment failure with PEG/RBV : Sofosbuvir (400 mg) and weight-based RBV ( mg) for 12 weeks cirrhotics may benefit from extension to 16 weeks HCV genotype 3, regardless of eligibility for IFN therapy or treatment failure with PEG/RBV : Sofosbuvir (400 mg) and weight-based RBV ( mg) for 24 weeks Alternative regimen: HCV genotype 2&3 PEG/RBV nonresponders: Sofosbuvir (400 mg) and weightbased RBV ( mg) plus weekly PEG for 12 weeks in IFN eligible patients Copyright 2014 American College of Gastroenterology 12
13 FUSION: Sofosbuvir + RBV by Fibrosis Level in Treatment-experienced Genotype Sof + RBV 12 Weeks Sof + RBV 16 Weeks SVR R12 (%) Jacobson, et al. NEJM 368: n/n = 25/26 23/23 6/10 7/9 0 No Cirrhosis Cirrhosis RBV = ribavirin VALENCE: Sofosbuvir + RBV for 24 weeks Genotype 3 IFN naïve, ineligible or treatment failures G weeks 24 SOF+RBV (n=250) Genotype 3 85 SVR 12 (%) 60 86/92 12/13 85/100 27/45 Noncirrhotic Cirrhotic Noncirrhotic Cirrhotic Naïve Treatment-experienced Zeuzem S et al N Engl J Med 2014; 370: Copyright 2014 American College of Gastroenterology 13
14 Interferon-Free, All Oral Regimens Other/Special Populations Paritapreivr/r, Ombitasvir, Dasabuvir with RBV for 24 weeks for Liver Transplant HCV Patients: Preliminary Efficacy Results s Percentage Patients 34/34 34/34 32/ /2626 No patient had breakthrough One patient had a relapse (post-treatment day 3) At the time of relapse, this patient had R155K in NS3 protease, M28T+Q30R in NS5A, and G554S+G557R in NS5B, none of which were present at baseline Kwo P, et al. 49th EASL; London, England; April 9-13, Abst. O114. Copyright 2014 American College of Gastroenterology 14
15 Virologic Response with SOF/LDV for 12 Weeks in HIV/HCV Coinfected Noncirrhotic, Treament Naïve Patients with Percentage of Patients h HCV RNA < LLOQ (ITT) ARV - 13/ 13 13/13 13/ 13 12/12 10/10 10/10 ARV + 37/37 37/37 30/30 22/22 Osinusi A et al. 49th EASL; London, England; April 9-13, Abst. O14. Summary: To be continued The next big advance is here: all oral therapies for genotype 1 that are FDA approved Sofosbuvir/ledipasvir: (no RBV) 8-12 weeks for naïve 24 weeks for non-responder cirrhotic patients Paritaprevir/Ombitasvir/dasabuvir±RBV (approval by end of 2014) 12 weeks for naïve, cirrhotic patients (with RBV) 24 weeks for Genotype 1a null responders 12 weeks no RBV for 1b non-cirrhotics Sofosbuvir/simeprevir also available, not licensed together yet Copyright 2014 American College of Gastroenterology 15
16 Summary: To be continued Genotype 2 has been largely solved (12-16 weeks) Genotype 3 treatment failure with cirrhosis is now the most problematic to treat Special populations are becoming not so special HIV/HCV patients Post OLT patients Access to therapies will be important The new components of treatment in HCV infection NS3 NS5b NS5a NS5b NNI Copyright 2014 American College of Gastroenterology 16
17 Paul Y. Kwo, MD, FACG Hepatitis C Therapy has Paralleled Helicobacter pylori Therapy HCV H pylori All Oral Therapy Duration 8-24 weeks Polymerase Inhibitor ± All Oral Therapy, single tablet Protease Inhibitor ± NS5a ± Non-nucleoside Inhibitor ± ribavirin Copyright 2014 American College of Gastroenterology 17
HCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationI nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione. la pratica clinica
I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione La revisione ii delle dll evidenze e indicazioni i iper la pratica clinica Marco Marzioni Segretario
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationMassimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Innovative strategies in viral hepatitis : Hepatitis C: Interferon and/or Ribavirin free regimens 10th International Workshop on
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationCan a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients?
Can a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients? Ira M. Jacobson, MD Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationGenotype 1 Treatment Naïve No Cirrhosis Options
Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationEd Gane NZ Liver Transplant Unit Auckland City Hospital
Clinical Management of Hepatitis C Patients Treat Now or Wait Ed Gane NZ Liver Transplant Unit Auckland City Hospital SVR24 rates with PEG/RBV by HCV genotype Data from the real-world PROPHESYS cohort
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More information